NCT00913341CompletedPhase 1
Bioavailability of Alprazolam Tablets
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Sandoz
- Enrollment
- 30
- Primary Endpoint
- Bioequivalence based on AUC and Cmax
Study Overview
Brief Summary
To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 50 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
Arms & Interventions
1
Experimental
Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Intervention: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals) (Drug)
2
Active Comparator
Alprazolam Tablets, 1 mg (The Upjohn Company)
Intervention: Alprazolam Tablets, 1 mg (The Upjohn Company) (Drug)
Outcomes
Primary Outcomes
Bioequivalence based on AUC and Cmax
Time Frame: 13 days
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 1
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mgAnxietyNCT00912145Sandoz26
Completed
Phase 1
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting ConditionsHealthyNCT01188057Actavis Inc.40
Completed
Phase 1
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting ConditionsHealthyNCT01188031Actavis Inc.40
Completed
Phase 1
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting ConditionsHealthyNCT00830024Teva Pharmaceuticals USA36
Completed
Phase 1
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting ConditionsHealthyNCT00829426Teva Pharmaceuticals USA32